Back to the atlasDownload source notes

October 27, 2026 — scheduled focused research update

Home · Latest · Milestones

All 32 active condition topics are represented below; the retained Sleep hub preserves history without duplicate monitoring. Each review is focused and incomplete. Full successful-check dates remain unchanged. Bulk registry retrieval is not complete clinical appraisal or a worldwide no-news determination. Source, publication, event, approval, verification and estimated completion dates remain distinct. Newly recovered older disclosures retain their original dates; historical baseline additions and repeated findings are excluded from alerts. No new distinct rumor alert was selected; unresolved original claims were revisited.

Findings

Coverage by topic

Whole-body MRI

Coverage: focused/incomplete. 0 newly recorded entries.

Searches: Whole-body MRI screening mortality/outcomes large-scale study September–October 2026; targeted primary journals and trial registry search.; Saved screening protocol refresh and paginated ClinicalTrials.gov updates from September 5.; Original Reddit whole-body MRI screening experiences, new study claims, and podcast/talk search.

Coverage and gaps: focused_incomplete. The October 22 noncontrast DWIBS breast-MRI paper (doi:10.3390/cancers18213417) could not be fully accessed after MDPI rate limits. Its indexed abstract explicitly describes preliminary non-population screening; do not transfer it to whole-body outcome evidence.; The August Cochrane whole-body MRI item is a review protocol, not a completed clinical-outcome review. An October 24 AI body-composition paper is not screening efficacy.; No full worldwide registry or conference sweep completed; ClinicalTrials.gov discovery is not exhaustive of CTIS/ISRCTN/ANZCTR/Chinese registries.; Not every retrieved discovery record or full publication/supplement has been appraised. Do not advance a full successful-check timestamp.; Original long-form podcast/talk/Q&A coverage is incomplete; search hits and repeated anecdotes do not establish confirmation.

Informal sources and unresolved claims: status: focused_incomplete; result: Original patient-experience posts and repeated older review claims did not yield a distinct, adequately sourced new screening-outcome rumor. No comprehensive podcast/talk census.

Sources checked:

Galleri and organ-specific cancer screening

Coverage: focused/incomplete. 5 newly recorded entries.

Searches: GRAIL clinical evidence index and October 15–26 primary conference slide/poster files: PF2 workup, real-world claims, psychological impact, false-positive behavior and standard-screening adherence.; FDA/GRAIL approval and September advisory followup; no final marketing authorization verified.; Paginated ClinicalTrials.gov saved and newly updated multi-cancer, breast, lung, colorectal and endometrial screening records.; Reddit Galleri approval predictions and podcast/talk screening claims; separate advisory vote, detection and clinical outcomes.

Coverage and gaps: focused_incomplete. No new whole-trial PF2 sensitivity/PPV or mortality analysis should be inferred from selected positive-screen workup denominators.; No numerical procedure-related adverse-event table in the new PF2 presentation; detailed safety counts remain an access/appraisal gap.; DWIBS noncontrast breast MRI full paper inaccessible (MDPI 429); no performance figures used.; NCT07892755 endometrial cfDNA case-control protocol was retrieved (512 planned; cancer/hyperplasia/healthy groups) but not selected as a validated screening result. Full tumor-genomics discovery requires further appraisal.; No full worldwide registry or conference sweep completed; ClinicalTrials.gov discovery is not exhaustive of CTIS/ISRCTN/ANZCTR/Chinese registries.; Not every retrieved discovery record or full publication/supplement has been appraised. Do not advance a full successful-check timestamp.; Original long-form podcast/talk/Q&A coverage is incomplete; search hits and repeated anecdotes do not establish confirmation.

Informal sources and unresolved claims: status: focused_incomplete; result: FDA-approval timing speculation persists; an advisory vote and sponsor optimism are not final approval. No new original-source confirmation or contradiction sufficient to change an existing rumor status was verified.

Sources checked:

Coverage: focused/incomplete. 7 newly recorded entries.

Searches: type: ClinicalTrials.gov paginated discovery; query: (obesity OR overweight OR GLP-1) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-09-05,2026-10-27]; total: 1049; retrieved: 1049; pages: 11; type: Named records; recordsReferencedInTopic: 28; retrievedInCombinedIndex: 28; type: Targeted primary and original informal searches; queries: October2026October23October27 retatrutide eloralintide EloraTZP AMPLIFY doses recruitment EASD trial results safety; ASC36 ASC39 olatorepatide HS20094 LEAP2 human trial primary sources; site:reddit.com Eloralintide GLP1ResearchTalk October2026 trial experience fatigue

Coverage and gaps: Focused partial review; all pages of specified ClinicalTrials.gov discovery retrieved and selected relevant records appraised. Worldwide full-topic review and baseline completion are NOT claimed.. Focused partial appraisal only. Complete ClinicalTrials.gov query retrieval is not exhaustive worldwide evidence review; independent non-U.S. registries, full conference audio/slides, all publications and a complete holds/discontinuations/harms census remain incomplete. Do not advance full successful-check timestamps or sleep baseline-complete flags.; EloraTZP exact doses/escalation and first dosing remain unpublic/unverified; sponsor/registry recruitment disagreement preserved.; Full EASD slide/audio follow-up and every new protocol not appraised. LY4167586 NCT07881887 and NKS-3 NCT07882654 remain leads; NKS-3 is modified-linoleic-acid fat-taste receptor research, not an incretin.; Semaglutide BARI-STEP registry calls an attrition-excluding population intention-to-treat; retain ambiguity rather than repair it.

Informal sources and unresolved claims: Targeted original Reddit and sponsor/interview lead searches sampled, not a complete podcast/transcript census. Re-read NoMoreFatShame ENLIGHTEN-6 account (October9 saved source; original accessible) and SOLIS-1 noargentinianbeef account (October8 saved source; previously inaccessible original now accessible). They describe appetite/sleep/skin/GI/fatigue experiences, with blinded assignment/dose and causality unverified. The SOLIS thread has a relative-age reply claiming severe fatigue on DACRA alone; exact posting date and treatment attribution were not independently established, so no new generalized safety alert. No validated efficacy, dose or approval rumor promoted.

Sources checked:

Muscle building and preservation

Coverage: focused/incomplete. 2 newly recorded entries.

Searches: Targeted registry discovery (28 retrieved records) and saved-program follow-up; selected osteoporosis/muscle and T1D lean-tissue protocols appraised.; Original regulator/sponsor/investigator/paper follow-up and targeted informal-source searches.

Coverage and gaps: focused_partial. COURAGE full in-press manuscript and complete BELIEVE withdrawal tables remain unrecovered. Trial-level worldwide coverage and independent functional follow-up remain incomplete.

Informal sources and unresolved claims: The enobosarm Cantor Phase 3 planning remark remains unconfirmed; no original new human result or first dosing corroborated. Reposts are not independent confirmation.

Sources checked:

Longevity and healthspan trials

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: type: ClinicalTrials.gov paginated discovery; query: (longevity OR healthspan OR metformin aging OR rapamycin aging OR senolytic) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-09-05,2026-10-27]; total: 76; retrieved: 76; pages: 1; type: Named records; recordsReferencedInTopic: 14; retrievedInCombinedIndex: 14; type: Targeted primary and original informal searches; queries: October2026 metformin rapamycin TAME REPROGRAM healthspan human trial results; PEARL24month Vitaei DOI followup; site:reddit.com longevity metformin rapamycin October2026 trial

Coverage and gaps: Focused partial review; all pages of specified ClinicalTrials.gov discovery retrieved and selected relevant records appraised. Worldwide full-topic review and baseline completion are NOT claimed.. Focused partial appraisal only. Complete ClinicalTrials.gov query retrieval is not exhaustive worldwide evidence review; independent non-U.S. registries, full conference audio/slides, all publications and a complete holds/discontinuations/harms census remain incomplete. Do not advance full successful-check timestamps or sleep baseline-complete flags.; TAME current funded/registered initiation not verified; AFAR direct page failed previously and indexed fundraising text is insufficient.; No actual REPROGRAM readout inferred from an elapsed October forecast. Complete healthspan-outcome literature and metformin harms review remains incomplete.

Informal sources and unresolved claims: Re-read Vitaei April11 PEARL24-month claim. It still asserts a follow-up; the offered DOI10.1111/acel.14056 remains unrelated to the claimed clinical report. Prior status persists: follow-up unconfirmed and citation contradicted as support. Targeted metformin/rapamycin/REPROGRAM/TAME informal searches yielded no validated new readout or funded start.

Sources checked:

Localized fat removal and cellulite

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: type: registry; window: 2026-09-05 through 2026-10-27; description: Paginated all ClinicalTrials.gov records matching topic query and modified in window; merged refresh of every saved NCT ID. Selective title/protocol/results appraisal, not all incidental matches.; recordsRetrieved: 155; namedTrialIdsRefreshed: NCT00675506; NCT02196831; NCT03375788; NCT04867434; NCT05445557; NCT05736107; NCT06256445; NCT06303570; NCT07140939; NCT07481734; NCT07608757; NCT07608770; NCT07802431; NCT07862920; NCT07864246; NCT07880301; errors: ; type: primary-literature; window: 2026-09-05 through 2026-10-27; description: Europe PMC indexed MED first-publication discovery; abstracts plus selected full papers reviewed. Indexed retrieval complete for query; appraisal selective.; hitsRetrieved: 37; sourceUrl: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22localized+fat%22+OR+%22cellulite%22+OR+%22tesamorelin%22+OR+%22CBL-514%22+OR+%22RZL-012%22+OR+%22lipedema%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-27%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; type: sponsor/regulator/informal; description: Targeted original Reddit and indexed podcast/talk searches for CBL-514, RZL-012, tesamorelin and fat/cellulite programs. Sponsor index and dated release checks.

Coverage and gaps: focused_incomplete; do not advance full successful-check timestamp. Worldwide completion is not established: CTIS, ChiCTR/jRCT and other national registries, every indexed article, every conference poster and unindexed social/audio sources were not exhaustively appraised. Keep the full successful-check timestamp unchanged.; No exhaustive independent review of all localized/visceral-fat interventions, lipedema devices or all cellulite procedures. No new randomized tesamorelin indication result verified.; SUPREME-01 recruiting and elapsed forecasts do not establish completed enrollment. Repeated stock stories misstate responder percentages as fat-volume loss and are not independent results.

Informal sources and unresolved claims: scope: Targeted original Reddit and indexed podcast/talk searches for CBL-514, RZL-012, tesamorelin and fat/cellulite programs. Sponsor index and dated release checks.; status: No selected new development rumor; self-sourcing/compounding anecdotes excluded. Reposted sponsor percentages are not independent confirmation.; limitations: Not a complete Reddit-comment or podcast-audio census.

Sources checked:

Broad cardiovascular prevention, lipids and screening

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: type: ClinicalTrials.gov paginated discovery; query: (hypercholesterolemia OR dyslipidemia OR lipoprotein OR atherosclerosis OR coronary artery calcium OR CCTA) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-09-05,2026-10-27]; total: 587; retrieved: 587; pages: 6; type: Named records; recordsReferencedInTopic: 21; retrievedInCombinedIndex: 21; type: Targeted primary and original informal searches; queries: October2026 lipid lowering cardiovascular outcomes VERVE PCSK9 Lp(a) EDIT401 enlicitide clinical trials; site:reddit.com VERVE LDL gene editing October2026 interview podcast

Coverage and gaps: Focused partial review; all pages of specified ClinicalTrials.gov discovery retrieved and selected relevant records appraised. Worldwide full-topic review and baseline completion are NOT claimed.. Focused partial appraisal only. Complete ClinicalTrials.gov query retrieval is not exhaustive worldwide evidence review; independent non-U.S. registries, full conference audio/slides, all publications and a complete holds/discontinuations/harms census remain incomplete. Do not advance full successful-check timestamps or sleep baseline-complete flags.; No new cardiovascular-event/mortality result was established by the selected newly appraised gene-editing protocol. Full VERVE, enlicitide, Lp(a), CAC/CCTA/AI screening and long-term outcome/safety literature review remains incomplete.; EDIT-401 AHA November 8 presentation is preclinical, not new human data.

Informal sources and unresolved claims: Targeted original Reddit/talk/podcast lead searches for VERVE, lipid editing, Lp(a) and broad prevention were sampled. No newly appraised original informal claim met the meaningful-update threshold; absence of a selected item is not exhaustive no-rumor coverage.

Sources checked:

Alzheimer's screening and therapies

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: Acumen October 26 primary earnings update plus ALTITUDE-AD registry; compare fresh sponsor forecast with stale 2025 registry.; CTAD November 16–19 upcoming program/timing and current Alzheimer trial development, safety, stop/hold and recruitment searches.; Saved Alzheimer registries and paginated discovery; inspect tau platform/TREMHANCE updates and newly posted early-human candidates.; Longo/LM11A-31 funding/trial-planning podcast claim, obicetrapib dementia inference and Acumen call-expectation searches.

Coverage and gaps: focused_incomplete. ALTITUDE full results not yet released; original October 26 webcast not listened to. Third-party transcript benchmark/ARIA expectations must not be treated as observed data.; No comprehensive CTAD abstract and all investigational Alzheimer program review. New healthy-volunteer records PF-08161842 and SHR3201 do not establish an Alzheimer efficacy result.; TREMHANCE and tau-platform recruiting status already saved; no duplicate alert solely because registry update date changed.; No full worldwide registry or conference sweep completed; ClinicalTrials.gov discovery is not exhaustive of CTIS/ISRCTN/ANZCTR/Chinese registries.; Not every retrieved discovery record or full publication/supplement has been appraised. Do not advance a full successful-check timestamp.; Original long-form podcast/talk/Q&A coverage is incomplete; search hits and repeated anecdotes do not establish confirmation.

Informal sources and unresolved claims: status: focused_incomplete; result: LM11A-31 further-trial funding plans and obicetrapib dementia hypotheses remain unconfirmed clinical-benefit claims. Acumen call commentary found in secondary transcripts was not promoted to actual efficacy/ARIA results; no new independently verified original informal signal selected.

Sources checked:

Coverage: focused/incomplete. 3 newly recorded entries.

Searches: CYB003 APPROACH October 27 registry update and human psychedelic discovery including depression, anxiety, PTSD and addiction.; COMP360/BPL-003/VLS-01 formal stage and announcement checks; separate mebufotenin, DMT and psilocybin.; Rhelion/Filament October 16 original proposed Belgian compassionate-use release.; Original October 26 shroomstocks discussion, FDA/Compass pricing podcast leads and trial-result rumor searches.

Coverage and gaps: focused_incomplete. APPROACH result table and complete adverse-event results not posted; do not infer success from completed status.; PACT structured enrollment 150 versus narrative 120 remains unresolved.; BPL-003 Phase 2b full publication/registry-result tables were not reappraised; an October Reddit lead could be a repost and is not a confirmed new paper.; Oregon psilocybin observational cohort August 19 and October 16 correction identified but not fully appraised; no observational efficacy or safety figures imported.; No final Belgian regulator authorization or exact PEX010 program dosing verified; no complete COMP360 FDA-submission file confirmed.; No full worldwide registry or conference sweep completed; ClinicalTrials.gov discovery is not exhaustive of CTIS/ISRCTN/ANZCTR/Chinese registries.; Not every retrieved discovery record or full publication/supplement has been appraised. Do not advance a full successful-check timestamp.; Original long-form podcast/talk/Q&A coverage is incomplete; search hits and repeated anecdotes do not establish confirmation.

Informal sources and unresolved claims: status: focused_incomplete; originalSources: url: https://www.reddit.com/r/shroomstocks/comments/1xfw66z/rshroomstocks_weekly_discussion_thread_october_26/; date: 2026-10-26; type: community discussion; comments incomplete; result: Existing COMP360 timing/approval inferences remain unconfirmed. New podcast/pricing leads were not fully reviewed and no new attributable signal selected. Viral mouse neuronal-regrowth stories excluded from formal human findings.

Sources checked:

Mental-health treatments, SSRIs and newer antidepressants

Coverage: focused/incomplete. 2 newly recorded entries.

Searches: Worldwide human mental-health treatment trial discovery beyond depression: panic/anxiety, OCD, PTSD, bipolar disorder and addiction.; Meltz panic CBT and SONATA focused-ultrasound OCD full protocols; PGx suicide-prevention cross-topic study.; MHRA October 15 antidepressant risk leaflet and October 26 repost context; avoid presenting established risks as a new FDA action.; Original Reddit patient accounts, antidepressant trial rumors and podcast/talk searches.

Coverage and gaps: focused_incomplete. Many broad registry results involve depression/anxiety incidentally; their retrieval is not a full therapeutic appraisal.; No exhaustive safety-label, mood-switching, function/relapse or long-term antidepressant trial review completed.; No complete original audio/transcript review for new psychiatric mechanism or trial-date claims.; No full worldwide registry or conference sweep completed; ClinicalTrials.gov discovery is not exhaustive of CTIS/ISRCTN/ANZCTR/Chinese registries.; Not every retrieved discovery record or full publication/supplement has been appraised. Do not advance a full successful-check timestamp.; Original long-form podcast/talk/Q&A coverage is incomplete; search hits and repeated anecdotes do not establish confirmation.

Informal sources and unresolved claims: status: focused_incomplete; result: Patient anecdotes and reposts of the MHRA communication did not establish a distinct new trial or regulatory event. No new original-source rumor selected; broad informal coverage remains incomplete.

Sources checked:

Bone health, joint preservation and cartilage repair

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: Targeted discovery (142 records, both pages retrieved), saved-program status checks, MITO results and the October 21 observational cohort appraised.; Original regulator/sponsor/investigator/paper follow-up and targeted informal-source searches.

Coverage and gaps: focused_partial. Senolytic osteoporosis NCT06018467 has no results in the original API despite an aggregator lead. TG-C ACTiVION I October forecast is still not verified; the month has not elapsed. Formal comparisons of fractures, healing and cartilage outcomes remain incomplete.

Informal sources and unresolved claims: Targeted Reddit/press leads mostly recycled older data. No new distinct sourced rumor promoted; original podcast/audio coverage remains incomplete.

Sources checked:

Liver health and noninvasive assessment

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: type: ClinicalTrials.gov paginated discovery; query: (MASH OR NASH OR liver fibrosis OR fatty liver OR noninvasive liver) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-09-05,2026-10-27]; total: 281; retrieved: 281; pages: 3; type: Named records; recordsReferencedInTopic: 16; retrievedInCombinedIndex: 16; type: Targeted primary and original informal searches; queries: October2026 MASH liver fibrosis FGF21 efruxifermin trial outcomes GSK4532990; Wegovy September2026 CHMP MASH October26 EMA product information; site:reddit.com MASH liver trial October2026

Coverage and gaps: Focused partial review; all pages of specified ClinicalTrials.gov discovery retrieved and selected relevant records appraised. Worldwide full-topic review and baseline completion are NOT claimed.. Focused partial appraisal only. Complete ClinicalTrials.gov query retrieval is not exhaustive worldwide evidence review; independent non-U.S. registries, full conference audio/slides, all publications and a complete holds/discontinuations/harms census remain incomplete. Do not advance full successful-check timestamps or sleep baseline-complete flags.; GSK4532990 results are model-predicted target engagement, not measured fibrosis/outcome efficacy. Detailed follow-on program context remains incomplete.; Wegovy EMA product-information PDF updated October 26 was downloaded: section4.1 remains weight-management indications. This does not explain the September CHMP agenda omission; the underlying procedural outcome remains unresolved.; Hibsago FDA October20 approval and PM647a first human AAT trial are root-owned; cross-link those findings rather than duplicate.

Informal sources and unresolved claims: Re-read original September18 NovoNordisk_Stock Wegovy-MASH agenda post. Current EMA EPAR/October26 PI does not establish the claimed procedural outcome; no confirmation/retraction inferred from omission. Targeted informal searches sampled MASH/FGF21/metabolic-liver leads; no other new claim promoted.

Sources checked:

Cancer treatment, vaccines and recurrence prevention

Coverage: focused/incomplete. 6 newly recorded entries.

Searches: FDA oncology approval notifications and full October 16/26 decision summaries; clinical setting, molecular selection, rPFS/OS and harms separated.; INTerpath-001 October 24 actual presentation; Moderna recap, ESMO release, targeted NEJM/full-paper and supplement search.; Paginated ClinicalTrials.gov cancer-treatment/vaccine and saved-trial updates; first-line CAR-T, bispecific-versus-ASCT and STARVACC protocols fully read.; Original SELLAS/REGAL October 26 discussion and sponsor-event status; rumors about imminent event count and trademark interpretations kept unconfirmed.

Coverage and gaps: focused_incomplete. Independent INTerpath journal full paper, complete supplements, and arm-level adverse-event tables not verified; do not promote secondary reported OS estimates.; Not all historical overlap-window oncology approvals were appraised (for example October 2 pirtobrutinib first-line CLL); this is an explicit regulatory coverage gap, not no news.; Some newly updated saved trials (ATOMIC, BAY2927088, DESTINY-Lung, SENTRY-CD19) and discovery records were refreshed without establishing a new material event. AZA-AEGEAN suspension remains previously reported; do not duplicate unchanged hold.; No full worldwide registry or conference sweep completed; ClinicalTrials.gov discovery is not exhaustive of CTIS/ISRCTN/ANZCTR/Chinese registries.; Not every retrieved discovery record or full publication/supplement has been appraised. Do not advance a full successful-check timestamp.; Original long-form podcast/talk/Q&A coverage is incomplete; search hits and repeated anecdotes do not establish confirmation.

Informal sources and unresolved claims: status: focused_incomplete; originalSources: url: https://www.reddit.com/r/sellaslifesciences/comments/1xfmsqz/sls_weekly_in_depth_discussion_thread_week_43_2026/; date: 2026-10-26; type: original community discussion; comments not fully accessible; result: Previously saved REGAL event-80 timing remains unconfirmed. Trademark/commercial-name speculation does not confirm efficacy, trial completion, or approval. No new rumor selected; complete comment and talk review remains a gap.

Sources checked:

Autoimmune disease and immune reset

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: 40 discovery records retrieved plus saved autoimmune program status; BMS October 23 and investigator October 26 Breakfree-2 materials appraised.; Original regulator/sponsor/investigator/paper follow-up and targeted informal-source searches.

Coverage and gaps: focused_partial. No primary confirmation of zola-cel voluntary-pause end or renewed dosing. Complete worldwide autoimmune entrants, late safety follow-up and trial tables remain incomplete.

Informal sources and unresolved claims: Mount Sinai IBD CAR-T planning remains an unresolved informal signal; no original announcement of a newly dosed clinical study verified.

Sources checked:

Non-opioid pain treatments

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: 71 discovery records retrieved plus saved non-opioid program checks, including suzetrigine protocols, HNK and SL-1002.; Original regulator/sponsor/investigator/paper follow-up and targeted informal-source searches.

Coverage and gaps: focused_partial. No material new numerical trial result selected from the appraised sources. Some registry records are incidental or not fully appraised; worldwide human trial and informal-source coverage remain incomplete.

Informal sources and unresolved claims: No distinct new original rumor selected from targeted web/Reddit leads; full podcast/talk transcripts not covered. HNK start remains an estimate, not a rumor-confirmed milestone.

Sources checked:

Kidney preservation and earlier detection

Coverage: focused/incomplete. 4 newly recorded entries.

Searches: type: ClinicalTrials.gov paginated discovery; query: (chronic kidney disease OR IgA nephropathy OR C3 glomerulopathy OR kidney preservation) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-09-05,2026-10-27]; total: 448; retrieved: 448; pages: 5; type: Named records; recordsReferencedInTopic: 15; retrievedInCombinedIndex: 15; type: Targeted primary and original informal searches; queries: October2026 ASN KidneyWeek pegcetacoplan VALIANT VALE76weeks ravulizumab IgAN I CAN FDA; finerenone FINEONE registry results CKD outcomes October2026; site:reddit.com kidney complement finerenone trial October2026

Coverage and gaps: Focused partial review; all pages of specified ClinicalTrials.gov discovery retrieved and selected relevant records appraised. Worldwide full-topic review and baseline completion are NOT claimed.. Focused partial appraisal only. Complete ClinicalTrials.gov query retrieval is not exhaustive worldwide evidence review; independent non-U.S. registries, full conference audio/slides, all publications and a complete holds/discontinuations/harms census remain incomplete. Do not advance full successful-check timestamps or sleep baseline-complete flags.; Ravulizumab current FDA label verified, but separate approval letter fetch returned404; exact FDA action date not independently recovered. Confirmatory eGFR result date not announced.; Original ASN abstracts recovered, but first-online dates, actual delivery, full poster tables, attrition and detailed harms remain incomplete.; FINE-ONE March efficacy already recorded; new registry safety categories should not trigger a duplicate efficacy alert.; Canonical FINE-ONE May pending-review wording is obsolete: FDA September2026 label215341s011 confirms T1D CKD indication. The old Bayer /en/us link404 redirects require replacement with current /en-us/united-states/news-and-stories/2026 path. Correct current status without treating it as newOctober27 approval.

Informal sources and unresolved claims: Sampled original Reddit/interview leads for complement therapies, finerenone and kidney preservation. No newly verified material rumor selected. ASN abstracts were kept as formal preliminary evidence, not rumor; sponsor presentation schedules alone were not treated as delivered outcomes.

Sources checked:

Hearing and vision preservation/restoration

Coverage: focused/incomplete. 0 newly recorded entries.

Searches: Hearing/vision preservation and restoration human readouts, regulator actions, safety, discontinuations and trial discovery from overlap window.; Saved BGE-102, DURAVYU, MCO-010, 4D-150 and AC102 registries/source updates; distinguish acquired disorders from inherited disease.; Original AC102 purported email and October tinnitus-research discussions; search sponsor/registry confirmation of conditional 2027 Phase 3/tinnitus plans.

Coverage and gaps: focused_incomplete. Broad discovery includes numerous incidental visual/hearing measurements; not all were appraised as therapy programs.; AC102 registry remains last posted January 16 with elapsed estimates; completion and new tinnitus/Phase 3 protocol were not officially confirmed.; AAO-HNS October tinnitus-guidance item identified but not fully appraised; no newly established therapy recommendation imported.; No complete worldwide inherited/acquired sensory trial, harms and device-approval inventory.; No full worldwide registry or conference sweep completed; ClinicalTrials.gov discovery is not exhaustive of CTIS/ISRCTN/ANZCTR/Chinese registries.; Not every retrieved discovery record or full publication/supplement has been appraised. Do not advance a full successful-check timestamp.; Original long-form podcast/talk/Q&A coverage is incomplete; search hits and repeated anecdotes do not establish confirmation.

Informal sources and unresolved claims: status: focused_incomplete; originalSources: url: https://www.reddit.com/r/tinnitusresearch/comments/1w1vebv/audiocure_ac102_update/; type: original anonymous account of purported company email; conditional plans; result: The previously saved AC102 conditional 2027 Phase 3/tinnitus claim remains unconfirmed; no new formal protocol or sponsor confirmation verified. Do not re-alert unchanged rumor.

Sources checked:

Hair loss, restoration and graying

Coverage: focused/incomplete. 2 newly recorded entries.

Searches: type: registry; window: 2026-09-05 through 2026-10-27; description: Paginated all ClinicalTrials.gov records matching topic query and modified in window; merged refresh of every saved NCT ID. Selective title/protocol/results appraisal, not all incidental matches.; recordsRetrieved: 151; namedTrialIdsRefreshed: NCT03570749; NCT03811912; NCT03899259; NCT05723198; NCT05910450; NCT05914805; NCT06018428; NCT06393452; NCT06692465; NCT06724614; NCT06972264; NCT07317544; NCT07340697; NCT07484061; NCT07810504; NCT07819435; NCT07839494; NCT07862374; NCT07863856; NCT07869199; errors: ; type: primary-literature; window: 2026-09-05 through 2026-10-27; description: Europe PMC indexed MED first-publication discovery; abstracts plus selected full papers reviewed. Indexed retrieval complete for query; appraisal selective.; hitsRetrieved: 218; sourceUrl: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22alopecia%22+OR+%22hair+loss%22+OR+%22hair+graying%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-27%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; type: sponsor/regulator/informal; description: Original BQ002/clascoterone rumor threads revisited; targeted tressless/grayhairreversal and named-program podcast/interview searches.

Coverage and gaps: focused_incomplete; do not advance full successful-check timestamp. Worldwide completion is not established: CTIS, ChiCTR/jRCT and other national registries, every indexed article, every conference poster and unindexed social/audio sources were not exhaustively appraised. Keep the full successful-check timestamp unchanged.; All emerging AGA/AA entrants and full safety tables were not exhaustively appraised. Some recently registered completed cosmetic studies have no posted results.; NCT07079657 is retrospectively registered and its status/start/masking fields conflict with the paper; preserve this unresolved discrepancy.; BioQ confirms a BQ002 canities candidate but no matched formal human-study registration or verified 2027 dosing milestone was established.

Informal sources and unresolved claims: scope: Original BQ002/clascoterone rumor threads revisited; targeted tressless/grayhairreversal and named-program podcast/interview searches.; status: Existing bq002_2026-05-01_reddit_phase1-2027 and clascoterone_2026-07-26_reddit_us-launch-inference remain unconfirmed, with no meaningful status change. October 24 compounding discussion is not trial-formulation equivalence or FDA hair-loss approval; October 4 PP405 pessimism is already saved.; limitations: No exhaustive comments or unindexed audio appraisal; do not repeat unchanged rumor alerts.

Sources checked:

Skin aging, laxity and regeneration

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: type: registry; window: 2026-09-05 through 2026-10-27; description: Paginated all ClinicalTrials.gov records matching topic query and modified in window; merged refresh of every saved NCT ID. Selective title/protocol/results appraisal, not all incidental matches.; recordsRetrieved: 129; namedTrialIdsRefreshed: NCT04717934; NCT06477172; NCT06724900; NCT07224880; NCT07661004; NCT07790237; NCT07849205; NCT07849556; NCT07853027; NCT07866131; NCT07870694; NCT07880756; NCT07881926; errors: ; type: primary-literature; window: 2026-09-05 through 2026-10-27; description: Europe PMC indexed MED first-publication discovery; abstracts plus selected full papers reviewed. Indexed retrieval complete for query; appraisal selective.; hitsRetrieved: 90; sourceUrl: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22skin+aging%22+OR+%22skin+laxity%22+OR+%22skin+rejuvenation%22+OR+%22wrinkles%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-27%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; type: sponsor/regulator/informal; description: Indexed Reddit, aesthetic-clinic claims and named product/podcast/interview searches sampled; original sponsor/regulatory statements preferred.

Coverage and gaps: focused_incomplete; do not advance full successful-check timestamp. Worldwide completion is not established: CTIS, ChiCTR/jRCT and other national registries, every indexed article, every conference poster and unindexed social/audio sources were not exhaustively appraised. Keep the full successful-check timestamp unchanged.; No complete census of new aesthetic-device clearances, worldwide launches or rare long-term adverse events.; Oral hyaluronan and pomegranate supplement papers surfaced but were not fully appraised for prespecified primary clinical outcomes; do not convert exploratory elasticity/biomarker changes into durable visible rejuvenation.; No new U.S. trenibotE resubmission or decision date was verified.

Informal sources and unresolved claims: scope: Indexed Reddit, aesthetic-clinic claims and named product/podcast/interview searches sampled; original sponsor/regulatory statements preferred.; status: No selected new rumor or material status change. Promotional procedure claims without a new formal human result were not promoted.; limitations: No exhaustive clinic-interview transcripts or podcast audio reviewed.

Sources checked:

Scar prevention, treatment and stretch marks

Coverage: focused/incomplete. 3 newly recorded entries.

Searches: type: registry; window: 2026-09-05 through 2026-10-27; description: Paginated all ClinicalTrials.gov records matching topic query and modified in window; merged refresh of every saved NCT ID. Selective title/protocol/results appraisal, not all incidental matches.; recordsRetrieved: 297; namedTrialIdsRefreshed: NCT02070809; NCT04506255; NCT05461755; NCT06033430; NCT06138964; NCT06944249; NCT07488988; NCT07635875; NCT07849010; NCT07850557; NCT07854470; NCT07868445; NCT07878390; NCT07880860; errors: ; type: primary-literature; window: 2026-09-05 through 2026-10-27; description: Europe PMC indexed MED first-publication discovery; abstracts plus selected full papers reviewed. Indexed retrieval complete for query; appraisal selective.; hitsRetrieved: 383; sourceUrl: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22scar%22+OR+%22keloid%22+OR+%22stretch+marks%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-27%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; type: sponsor/regulator/informal; description: Original verteporfin Reddit discussion and indexed clinical talk/podcast leads sampled; Syntara original index checked.

Coverage and gaps: focused_incomplete; do not advance full successful-check timestamp. Worldwide completion is not established: CTIS, ChiCTR/jRCT and other national registries, every indexed article, every conference poster and unindexed social/audio sources were not exhaustively appraised. Keep the full successful-check timestamp unchanged.; No full appraisal of every new keloid, donor-site, stretch-mark and scar-device record. New RECELL donor-site registration surfaced without a selected efficacy claim.; Verteporfin forum claims of ongoing trials before formal recruitment updates do not prove dosing, scarless regeneration or follicle recovery.

Informal sources and unresolved claims: scope: Original verteporfin Reddit discussion and indexed clinical talk/podcast leads sampled; Syntara original index checked.; status: No selected new rumor/status change. Recruiting SCARFREE-001 does not validate every earlier forum account or self-experiment claim.; limitations: Physician self-experiments and unavailable full audio were not treated as formal comparative outcomes.

Sources checked:

Facial volume restoration and contour

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: type: registry; window: 2026-09-05 through 2026-10-27; description: Paginated all ClinicalTrials.gov records matching topic query and modified in window; merged refresh of every saved NCT ID. Selective title/protocol/results appraisal, not all incidental matches.; recordsRetrieved: 150; namedTrialIdsRefreshed: NCT04769193; NCT06351358; NCT07032597; NCT07419854; NCT07805889; NCT07855224; NCT07856797; NCT07877870; errors: ; type: primary-literature; window: 2026-09-05 through 2026-10-27; description: Europe PMC indexed MED first-publication discovery; abstracts plus selected full papers reviewed. Indexed retrieval complete for query; appraisal selective.; hitsRetrieved: 62; sourceUrl: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22dermal+filler%22+OR+%22facial+volume%22+OR+%22fat+grafting%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-27%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; type: sponsor/regulator/informal; description: Original sponsor index, indexed Reddit and aesthetic interview/podcast leads sampled.

Coverage and gaps: focused_incomplete; do not advance full successful-check timestamp. Worldwide completion is not established: CTIS, ChiCTR/jRCT and other national registries, every indexed article, every conference poster and unindexed social/audio sources were not exhaustively appraised. Keep the full successful-check timestamp unchanged.; No complete review of every filler, fat-graft, implant and facial-contour device program or delayed-event surveillance source.; Belotero Volume October 14 and Intense December 1 launch dates in prior sponsor context were forecasts; clinic advertisements alone did not verify nationwide availability.

Informal sources and unresolved claims: scope: Original sponsor index, indexed Reddit and aesthetic interview/podcast leads sampled.; status: No selected new development rumor; marketing and local clinic availability do not prove nationwide product launch or comparative outcomes.; limitations: No exhaustive clinic rollout or full audio/transcript census.

Sources checked:

Pigmentation and uneven skin tone

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: type: registry; window: 2026-09-05 through 2026-10-27; description: Paginated all ClinicalTrials.gov records matching topic query and modified in window; merged refresh of every saved NCT ID. Selective title/protocol/results appraisal, not all incidental matches.; recordsRetrieved: 81; namedTrialIdsRefreshed: NCT03926845; NCT04052425; NCT04057573; NCT06113445; NCT06113471; NCT06118411; NCT07136766; NCT07820098; NCT07840820; NCT07865312; NCT07876323; NCT07881328; NCT07881367; errors: ; type: primary-literature; window: 2026-09-05 through 2026-10-27; description: Europe PMC indexed MED first-publication discovery; abstracts plus selected full papers reviewed. Indexed retrieval complete for query; appraisal selective.; hitsRetrieved: 164; sourceUrl: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22melasma%22+OR+%22vitiligo%22+OR+%22hyperpigmentation%22+OR+%22solar+lentigines%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-27%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; type: sponsor/regulator/informal; description: Original EB06 Reddit discussions and indexed vitiligo/melasma/repigmentation interview/talk leads sampled.

Coverage and gaps: focused_incomplete; do not advance full successful-check timestamp. Worldwide completion is not established: CTIS, ChiCTR/jRCT and other national registries, every indexed article, every conference poster and unindexed social/audio sources were not exhaustively appraised. Keep the full successful-check timestamp unchanged.; No full appraisal of every melasma/PIH/lentigines program or pediatric vitiligo registration; new pediatric upadacitinib NCT07896434 is a lead, not an appraised result.; EB06 exact first participant dosing and activation of U.S. sites are not confirmed by an estimated registry start.

Informal sources and unresolved claims: scope: Original EB06 Reddit discussions and indexed vitiligo/melasma/repigmentation interview/talk leads sampled.; status: The formal EB06 program is now documented; older speculation about superior benefit, absence of JAK-class warnings or launch timing remains unproven. No new efficacy rumor selected.; limitations: Older threads are not independent confirmation of a sponsor forecast or safety advantage.

Sources checked:

Acne and rosacea

Coverage: focused/incomplete. 0 newly recorded entries.

Searches: type: registry; window: 2026-09-05 through 2026-10-27; description: Paginated all ClinicalTrials.gov records matching topic query and modified in window; merged refresh of every saved NCT ID. Selective title/protocol/results appraisal, not all incidental matches.; recordsRetrieved: 73; namedTrialIdsRefreshed: NCT05296629; NCT05343455; NCT06090721; NCT06248008; NCT06316297; NCT06952517; NCT07521462; NCT07681271; NCT07805655; NCT07854418; NCT07863193; NCT07866105; NCT07866131; NCT07881315; NCT07883538; errors: ; type: primary-literature; window: 2026-09-05 through 2026-10-27; description: Europe PMC indexed MED first-publication discovery; abstracts plus selected full papers reviewed. Indexed retrieval complete for query; appraisal selective.; hitsRetrieved: 159; sourceUrl: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22acne%22+OR+%22rosacea%22+OR+%22denifanstat%22+OR+%22B244%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-27%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; type: sponsor/regulator/informal; description: Targeted original Reddit searches and indexed denifanstat/rosacea podcast/talk or interview leads sampled; original Sagimet release chronology checked.

Coverage and gaps: focused_incomplete; do not advance full successful-check timestamp. Worldwide completion is not established: CTIS, ChiCTR/jRCT and other national registries, every indexed article, every conference poster and unindexed social/audio sources were not exhaustively appraised. Keep the full successful-check timestamp unchanged.; October 21 JAAD spironolactone/chronic-kidney-disease acne safety paper PMID42906779 surfaced, but no abstract or complete text was retrieved; effect sizes, denominators and clinical conclusions remain unverified. Retry this specifically.; TVB-3567 topical FASN Phase 1 NCT06989840 is a human-stage lead (first registered May 2025, updated October 21); not fully appraised for baseline or results, and not a new October first registration.; No exhaustive global approval/device, rosacea phenotype or long-term safety review.

Informal sources and unresolved claims: scope: Targeted original Reddit searches and indexed denifanstat/rosacea podcast/talk or interview leads sampled; original Sagimet release chronology checked.; status: No selected new development rumor. October 9 sponsor/index repetition of October 1 extension data is not a new result.; limitations: Full Reddit comments, audio and full CKD safety paper remain unappraised.

Sources checked:

Dental alignment, regeneration and repair

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: type: registry; window: 2026-09-05 through 2026-10-27; description: Paginated all ClinicalTrials.gov records matching topic query and modified in window; merged refresh of every saved NCT ID. Selective title/protocol/results appraisal, not all incidental matches.; recordsRetrieved: 192; namedTrialIdsRefreshed: NCT02954133; NCT05213338; NCT05361616; NCT06685029; NCT06749977; NCT06881615; NCT07176871; NCT07496892; NCT07638397; NCT07664046; NCT07842120; NCT07859358; NCT07867067; NCT07881146; NCT07883005; errors: ; type: primary-literature; window: 2026-09-05 through 2026-10-27; description: Europe PMC indexed MED first-publication discovery; abstracts plus selected full papers reviewed. Indexed retrieval complete for query; appraisal selective.; hitsRetrieved: 433; sourceUrl: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22orthodontic%22+OR+%22aligner%22+OR+%22tooth+regeneration%22+OR+%22enamel%22+OR+%22periodontal+regeneration%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-27%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; type: sponsor/regulator/informal; description: Original Toregem index, viral/removed Reddit tooth-regrowth posts and indexed regeneration/3D-printing podcast leads sampled.

Coverage and gaps: focused_incomplete; do not advance full successful-check timestamp. Worldwide completion is not established: CTIS, ChiCTR/jRCT and other national registries, every indexed article, every conference poster and unindexed social/audio sources were not exhaustively appraised. Keep the full successful-check timestamp unchanged.; No complete global coverage of orthodontic materials, directly printed/shape-memory appliances, remote monitoring, treatment acceleration or long-term retention.; Aligner BPA/BPS saliva study PMID42905298 was abstract-appraised only: a biomarker concentration does not establish appliance origin, systemic dose or clinical harm.; New FM clear-aligner single-arm registration NCT07896369 surfaced but was not fully appraised. Root/gum and final-bite/retention outcomes should remain separate from manufacturing speed and early movement.; No complete primary-source confirmation of rumored 2030 tooth-regrowth availability; congenital tooth agenesis is distinct from acquired loss.

Informal sources and unresolved claims: scope: Original Toregem index, viral/removed Reddit tooth-regrowth posts and indexed regeneration/3D-printing podcast leads sampled.; status: No selected new rumor/status change. Repeated 2030 availability hopes are not sponsor-confirmed access; October 20 exhibition news is not a dosing or efficacy milestone.; limitations: Removed originals and absent full audio/transcripts limit attribution; do not invent content.

Sources checked:

Allergy and airway disease

Coverage: focused/incomplete. 3 newly recorded entries.

Searches: 173 initial phase-limited discovery records and 409 all-phase interventional records retrieved; targeted PM647a, tozorakimab and new OIT protocols appraised.; Original regulator/sponsor/investigator/paper follow-up and targeted informal-source searches.

Coverage and gaps: focused_partial. Bulk retrieval is not complete appraisal. Quantitative PROSPERO extension safety tables, actual PM647a first dose and a verified tozorakimab regulatory decision remain gaps.

Informal sources and unresolved claims: Patient discussions about existing asthma medicines are not development milestones. No distinct new original rumor selected; broader podcasts/talks remain incomplete.

Sources checked:

Infectious-disease prevention and treatment

Coverage: focused/incomplete. 4 newly recorded entries.

Searches: 427 initial phase-limited records and 1,053 all-phase interventional records retrieved across all pages; FDA label, HBV approval, FLINTLOCK, combination-vaccine and Shigella records appraised.; Original regulator/sponsor/investigator/paper follow-up and targeted informal-source searches.

Coverage and gaps: focused_partial. Actual Hibsago commercial launch/coverage, full worldwide antibiotic/phage/antiviral appraisal and independent AI-phage patient outcomes remain gaps. Regulatory workshop timing is separate from efficacy.

Informal sources and unresolved claims: October 24/21 Reddit AI-phage reposts trace to the already-recorded October 20 sponsor statement; no new patient outcome independently confirmed. An October 26 phage discussion points to a formal CF pilot but supplies no result. Earlier adibelivir administrative rumor remains unconfirmed; original audio coverage incomplete.

Sources checked:

Genetic screening and risk prediction

Coverage: focused/incomplete. 3 newly recorded entries.

Searches: ASHG 2026 primary conference news and investigator study details for newborn genomics, cascade testing, rapid sequencing, PRS, reproductive screening and pharmacogenomics.; Paginated ClinicalTrials.gov new/updated genetic-screening and risk-prediction studies since overlap window.; Nucleus/Vitruvian embryo IQ-model claim and original-source/reddit status searches; no actual offspring-benefit result verified.

Coverage and gaps: focused_incomplete. Complete ASHG abstracts, ancestry-specific performance, long-term outcome and harm tables were not fully appraised.; No exhaustive reassessment of PRS calibration/clinical benefit, carrier screening, PGT-M/SR/A/P, or all pharmacogenomic protocols.; No prospective long-term offspring outcome data verified for embryo polygenic selection; modeling claims remain separate.; No full worldwide registry or conference sweep completed; ClinicalTrials.gov discovery is not exhaustive of CTIS/ISRCTN/ANZCTR/Chinese registries.; Not every retrieved discovery record or full publication/supplement has been appraised. Do not advance a full successful-check timestamp.; Original long-form podcast/talk/Q&A coverage is incomplete; search hits and repeated anecdotes do not establish confirmation.

Informal sources and unresolved claims: status: focused_incomplete; result: Previously saved Nucleus/Vitruvian IQ-improvement claim remains a model/marketing claim without measured offspring confirmation. No new original transcript or regulatory development verified; do not re-alert unchanged status.

Sources checked:

Insomnia

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: type: ClinicalTrials.gov paginated discovery; query: (insomnia OR sleep initiation OR sleep maintenance) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-07-29,2026-10-27]; total: 1788; retrieved: 1788; pages: 18; type: Named records; recordsReferencedInTopic: 9; retrievedInCombinedIndex: 9; type: Targeted primary and original informal searches; queries: October2026 Idorsia daridorexant pediatric SleepEurope firstdose total sleep time abstract; insomnia sleep onset maintenance architecture trials October2026 safety; site:reddit.com insomnia daridorexant October2026 trial podcast

Coverage and gaps: Focused partial review; all pages of specified ClinicalTrials.gov discovery retrieved and selected relevant records appraised. Worldwide full-topic review and baseline completion are NOT claimed.. Focused partial appraisal only. Complete ClinicalTrials.gov query retrieval is not exhaustive worldwide evidence review; independent non-U.S. registries, full conference audio/slides, all publications and a complete holds/discontinuations/harms census remain incomplete. Do not advance full successful-check timestamps or sleep baseline-complete flags.; Detailed pediatric abstract recovered; manuscript remains under review, full arm denominators and durable developmental/remission/safety outcomes unknown.; Broad insomnia query includes many incidental sleep references; all1788 retrievals were not clinically appraised. Full architecture/long-term harms and complete conventional-drug/digital-therapy literature remains incomplete.

Informal sources and unresolved claims: Targeted Reddit and talk/interview leads sampled daridorexant, conventional insomnia drugs and sleep maintenance/onset. No new original informal program or safety signal was selected beyond formal pediatric results; this is not a full transcript or adverse-event census.

Sources checked:

Obstructive sleep apnea

Coverage: focused/incomplete. 3 newly recorded entries.

Searches: type: ClinicalTrials.gov paginated discovery; query: (obstructive sleep apnea) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-07-29,2026-10-27]; total: 147; retrieved: 147; pages: 2; type: Named records; recordsReferencedInTopic: 7; retrievedInCombinedIndex: 7; type: Targeted primary and original informal searches; queries: October2026 CHEST AD109 menopause hypoxic burden blood pressure original abstract; retatrutide OSA NEJMoa2611477 October21 AHI; site:reddit.com SleepApnea AD109 trial October2026 interview

Coverage and gaps: Focused partial review; all pages of specified ClinicalTrials.gov discovery retrieved and selected relevant records appraised. Worldwide full-topic review and baseline completion are NOT claimed.. Focused partial appraisal only. Complete ClinicalTrials.gov query retrieval is not exhaustive worldwide evidence review; independent non-U.S. registries, full conference audio/slides, all publications and a complete holds/discontinuations/harms census remain incomplete. Do not advance full successful-check timestamps or sleep baseline-complete flags.; AD109 CHEST original menopause, hypoxic-burden/BP and per-protocol PRO tables still not recovered; sponsor schedule and investigator interview are not equivalent to accessible original results.; Dedicated retatrutide OSA abstract recovered; full NEJM body/supplement returned403, so detailed GI/discontinuation denominators remain a gap.; cMAP protocol narrative says participant-blinded while structured masking is NONE; unresolved.

Informal sources and unresolved claims: Rechecked October26 HCPLive ReenaMehra investigator interview as a secondary/informal lead, with October22 interview already recorded; original post-hoc tables remain missing. It does not establish comparative clinical-outcome superiority. Sampled OSA/AD109/PAP/device Reddit and interview leads without promoting anecdotes to efficacy.

Sources checked:

Narcolepsy & excessive sleepiness

Coverage: focused/incomplete. 0 newly recorded entries.

Searches: type: ClinicalTrials.gov paginated discovery; query: (narcolepsy OR idiopathic hypersomnia OR orexin agonist) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-07-29,2026-10-27]; total: 28; retrieved: 28; pages: 1; type: Named records; recordsReferencedInTopic: 8; retrievedInCombinedIndex: 8; type: Targeted primary and original informal searches; queries: October2026 oveporexton TAK360 ALKS2680 orexin clinical trials FDA DEA scheduling; site:reddit.com Narcolepsy TAK360 Kyra orexin trial nighttime fragmentation

Coverage and gaps: Focused partial review; all pages of specified ClinicalTrials.gov discovery retrieved and selected relevant records appraised. Worldwide full-topic review and baseline completion are NOT claimed.. Focused partial appraisal only. Complete ClinicalTrials.gov query retrieval is not exhaustive worldwide evidence review; independent non-U.S. registries, full conference audio/slides, all publications and a complete holds/discontinuations/harms census remain incomplete. Do not advance full successful-check timestamps or sleep baseline-complete flags.; No new DEA scheduling or actual U.S. oveporexton launch verified; Japan/China October15 launch already recorded.; TGA priority determination lapsed October2; a later crawl is neither approval nor rejection.; TAK-360 LTE NCT07646678 current recruiting record retrieved, but it is already recorded and is not a new trial start; full Phase3 harms/architecture and wider global program review incomplete.

Informal sources and unresolved claims: Re-read original Narcolepsy TAK-360/Kyra thread, including statistics_squirrel account of wakefulness versus nighttime fragmentation at higher dose. Exact source date remains unknown (prior verificationOctober16), assignment/dose/causality unverified. Claim remains unresolved; no repeated alert. Other orexin/oveporexton original informal leads sampled; reposts are not independent confirmation.

Sources checked:

Circadian rhythm disorders

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: type: ClinicalTrials.gov paginated discovery; query: (circadian OR delayed sleep wake OR shift work disorder) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-07-29,2026-10-27]; total: 351; retrieved: 351; pages: 4; type: Named records; recordsReferencedInTopic: 5; retrievedInCombinedIndex: 5; type: Targeted primary and original informal searches; queries: October2026 circadian DSPD Non24 tasimelteon shiftwork SmartEnLite clinical trial; site:reddit.com DSPD Non24 October2026 trial sleep

Coverage and gaps: Focused partial review; all pages of specified ClinicalTrials.gov discovery retrieved and selected relevant records appraised. Worldwide full-topic review and baseline completion are NOT claimed.. Focused partial appraisal only. Complete ClinicalTrials.gov query retrieval is not exhaustive worldwide evidence review; independent non-U.S. registries, full conference audio/slides, all publications and a complete holds/discontinuations/harms census remain incomplete. Do not advance full successful-check timestamps or sleep baseline-complete flags.; SmartEnLite protocol now appraised; wearable sleep/rhythm metrics do not establish PSG architecture or dementia disease modification.; Other shift-work, DSPD/Non24 treatment/harm and global registry coverage remains incomplete; no new result inferred from registry timing.

Informal sources and unresolved claims: Sampled original DSPD/Non24/shift-work Reddit discussions and interview/talk leads. Patient burden reports are not controlled evidence; no new appraised clinical/program rumor selected.

Sources checked:

Restless legs syndrome

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: type: ClinicalTrials.gov paginated discovery; query: (restless legs syndrome) AND AREA[StudyType]INTERVENTIONAL AND AREA[LastUpdatePostDate]RANGE[2026-07-29,2026-10-27]; total: 13; retrieved: 13; pages: 1; type: Named records; recordsReferencedInTopic: 8; retrievedInCombinedIndex: 8; type: Targeted primary and original informal searches; queries: October2026 restless legs TOMAC Nidra dopaminergic augmentation trial; site:reddit.com RestlessLegs Nidra TOMAC October2026 trial

Coverage and gaps: Focused partial review; all pages of specified ClinicalTrials.gov discovery retrieved and selected relevant records appraised. Worldwide full-topic review and baseline completion are NOT claimed.. Focused partial appraisal only. Complete ClinicalTrials.gov query retrieval is not exhaustive worldwide evidence review; independent non-U.S. registries, full conference audio/slides, all publications and a complete holds/discontinuations/harms census remain incomplete. Do not advance full successful-check timestamps or sleep baseline-complete flags.; CT10 stale February9 record still NYR despite April estimate; actual recruitment/start unknown.; Full device/iron/medicine safety census and AASM/2026 algorithm source comparison remain incomplete. No new efficacy inferred from patient anecdotes.

Informal sources and unresolved claims: Sampled original RestlessLegs/Nidra/TOMAC discussions about response, discomfort and insurer approval/denial. Individual experience is not comparative efficacy or general coverage; no newly appraised meaningful rumor promoted.

Sources checked:

Homepage and publication

The October 3 EloraTZP feature was reviewed. It remains a matched-arm efficacy/harms comparison; the undated sponsor recruitment listing does not disclose Phase 3 doses or results. The current feature renderer is specific to weight-loss comparisons, so the new HBV, renal, oncology, screening and safety findings are presented through the current signals, precise notes and frontier records. A broader homepage feature presentation remains an editorial follow-up, rather than mislabeling another disease’s findings in a weight chart. Source/selection dates remain distinct from review date. Historical numerical plot data are preserved.

The public projection excludes personal context and retains exact evidence passages. Release validators and native deployment status verify this background publication; no browser QA is claimed. The publication receipt is written privately after successful deployment. If publication fails, the canonical notebook remains current and the website is marked stale.